Herein we present a general protocol for the functionalization of biomolecules with an organotrifluoroborate moiety so that they can be radiolabeled with aqueous 18 F fluoride ( 18 F − ) and used for positron emission tomography (pet) imaging. among the b + -emitting radionuclides, fluorine-18 ( 18 F) is the isotope of choice for pet, and it is produced, on-demand, in many hospitals worldwide. organotrifluoroborates can be 18 F-labeled in one step in aqueous conditions via 18 F-19 F isotope exchange. this protocol features a recently designed ammoniomethyltrifluoroborate, and it describes the following: (i) a synthetic strategy that affords modular synthesis of radiolabeling precursors via a copper-catalyzed 'click' reaction; and (ii) a one-step 18 F-labeling method that obviates the need for Hplc purification. Within 30 min, 18 F-labeled pet imaging probes, such as peptides, can be synthesized in good chemical and radiochemical purity (>98%), satisfactory radiochemical yield of 20-35% (n > 20, non-decay corrected) and high specific activity of 40-111 GBq/mmol (1.1-3.0 ci/mmol). the entire procedure, including the precursor preparation and 18 F radiolabeling, takes 7-10 d.
IntroDuctIon
PET is a fast-expanding, noninvasive imaging technology for visualizing and quantifying the dynamic distribution of target-specific ligands [1] [2] [3] [4] . Peptides, which are a class of relatively large water-soluble molecules with good target selectivity, often demonstrate highcontrast tumor-specific PET images, and thus they are promising imaging agents. A one-step 18 F-labeling method, which is sufficiently versatile to afford broad applications for most peptides, has been a longstanding challenge in radiochemistry 5, 6 . To achieve this goal, several approaches have been reported over the past few years that represent substantial advances in the radiolabeling of peptides and small molecules 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] . However, to date, most of the reported strategies require anhydrous conditions, which involve an azeotropic 'drying' procedure that enhances the reactivity of 18 F − , thereby ensuring good radiochemical yields 16 . Furthermore, to achieve high purity and high specific activity, which defines as GBq/µmol (Ci/µmol) and represents an impartial standard of radiotracer quality, time-consuming HPLC purification is often required 17 . These laborious procedures, such as azeotropic drying and HPLC purification, often reduce the radiochemical yield, while at the same time they increase the risk of synthetic failure. To solve these problems, a one-step and easy-to-follow protocol is described here for peptide radiolabeling that is based on the use of a recently developed organotrifluoroborate 18 .
In 2005, the Perrin group published a proof-of-concept study that described the labeling of an aryltrifluoroborate as a radiosynthon that could be 18 F labeled in aqueous conditions 19 . In the following years, this research group obtained promising biological data using this approach to develop PET imaging agents 20, 21 . Despite this initial success, early reports on PET imaging agents obtained via boron-mediated 18 F capture suffered from several apparent drawbacks 10 , namely, (i) insufficient in vivo stability, (ii) limited specific activity and (iii) stepwise and laborious operational procedure.
Over the past few years, most of these disadvantages have been addressed. The first problem was solved by designing and synthesizing a new generation of organotrifluoroborates that are stable in vivo 22, 23 . The second problem was largely solved by exploring 18 F radiolabeling at high levels of activity to increase the specific activity of 18 F radiotracers up to ~555 GBq/µmol (refs. 7,24) , which is orders of magnitude higher than in our previous reports [25] [26] [27] . Nevertheless, to advance this approach to a general and clinician-friendly method, we developed a novel B-18 F radiosynthon by screening a series of organotrifluoroborates 22 . This compound combines high in vivo stability, synthetic and bioconjugation simplicity, and convenient 18 F-labeling technology, which is based on 18 F- 19 F isotope exchange (IEX) of the 19 F-containing modified biomolecule 28 , and it represents the core of this protocol and has smoothly solved the third problem 22 . On the basis of this method, a number of bioligands have been radiolabeled and evaluated, and some of them have demonstrated excellent in vivo performance 18, [29] [30] [31] . Particularly, ammoniomethyltrifluoroborate (AMBF 3 )-TATE ( Fig. 1) , which is an octreotate derivative, showed excellent somatostatin receptor imaging properties, and the relevant bench-to-bedside translation is now underway 29 .
In contrast to mainstream 18 F-labeling methods, which either involve multiple steps or are water sensitive 32 , this approach has a one-step radiolabeling reaction, and the intermediates are stable in water. For large doses of 18 F − , a small quaternary methyl amine (µ-QMA) cartridge can be used (instead of performing azeotropic distillation) to concentrate the radioactivity before radiolabeling. In this approach, Curie levels of 18 F − can be directly eluted with <60 µl of saline (recovery rate: >95%, n > 50), and no further concentration is necessary (Step 17A; concentration by azeotropic distillation is still advisable for lower 18 F − doses-e.g., 50 mCi doses).
In 18 F-19 F IEX, the chemical structure of the radiolabeled product is identical to that of the precursor. In this case, a simple Sep-Pak purification affords the tracer in high radiochemical purity, and no HPLC purification is required. Furthermore, because of its operational simplicity, the radiolabeling can be simply performed with remote telemanipulators in a fully shielded hot cell. Thus, Curie levels of radioactivity are routinely used and a >7.4 GBq (>200 mCi) product can be reproducibly obtained at high specific activity. A limitation of this protocol is that when starting with a small amount of 18 F − (e.g., 50 mCi) for radiolabeling, as described in Step 17B, an azeotropic-concentrating procedure will be recommended in order to obtain the radiotracer of high specific activity. Overall, this protocol provides researchers a user-friendly tool that can overcome the challenges of preparing 18 F-labeled PET tracers.
In summary, this protocol simplifies the radiosynthesis of 18 F-labeled biomolecules, an improvement that will potentially promote the development of new PET tracers and accelerate their use from the bench to bedside. Herein, we describe the detailed protocols of (i) µ-QMA cartridge assemblage, (ii) coppercatalyzed radiosynthon conjugation and (iii) 18 F-19 F IEX.
Experimental design
This protocol describes the synthesis of [ 18 F]BF 3 -conjugated PET imaging probes. As a representative, [ 18 F]AMBF 3 -TATE is synthesized and used as an actual example to implement this approach. The procedure is outlined in Figure 1 . This protocol is generally suitable for 18 F labeling at the N termini of peptides; however, the authors would recommend the readers to implement the PROCEDURE exactly as detailed, so as to acquaint themselves with it, before moving on to using a different fluorinated compound. For very acid-sensitive or fragile peptides, one-pot two-step approaches can be considered 33 . In addition to radiolabeling peptides, this method can also be used to radiolabel other molecules after minor modification. The precursors will be prepared in similar manners by conjugating alkynyl AMBF 3 on biomolecule azide via copper-catalyzed 'click' reaction.
As a general applicable radiosynthon, the preparation of alkynyl AMBF 3 (Fig. 2) has been described in detail in this protocol. The peptide azide can be prepared either using solid-phase synthesis (as described in this PROCEDURE) or in liquid phase by directly conjugating azidoacetic acid on an amine-terminated peptide. In addition, there are many publications that describe how to prepare other types of azide compounds, and there are also commercially available azides that could be used.
The crucial step of this protocol is 18 F labeling, and the key factor for this step is the reaction pH. On the basis of our previous studies, a pH of 2-2.5 generally gives better radiochemical yield and lower by-product (boronic acid) levels than other conditions 34 . To maintain the reaction pH within the desired window, a series of buffers were screened and eventually a pyridazine-HCl buffer was chosen for BF 3 -mediated 18 F labeling. A pyridazine-HCl buffer was chosen not only for its ideal pK a but also because of its high solubility in water and low toxicity (LD 50 in mice is >2.6 g/kg). The experimental details for the preparation and use of this buffer are described in the Reagent Setup and
Step 17 of the PROCEDURE, respectively.
Before radiolabeling, the 18 F − starting solution needs to be concentrated. By using an amount of radioactive precursor that affords 1Curie level of radioactivity (~37 GBq), which can be easily obtained in many clinical PET centers, the azeotropic evaporation step can be obviated, as the 18 F − can be concentrated by using a µ-QMA cartridge. The details and tips related to the preparation of this cartridge are reported in Step 17A(i-vi) of the PROCEDURE. In this case, noncarrier added 18 F − is directly eluted into the reaction vial with ~60 µl of saline solution, and the total reaction volume is ~150 µl. By starting with 100 nmol of precursor, generally 200 mCi (7.4 GBq) of product can be obtained by the end of synthesis (EOS) to give the specific activity of 2.0 Ci/µmol (74 GBq/µmol). However, if you are starting with ~50 mCi of 18 F − (~1.85 GBq), which is more suitable for research purpose or preclinical studies, azeotropic evaporation is highly recommended in order to achieve a good radiochemical yield, as well as high specific activity (Step 17B(i-v)). In such cases, <10 nmol of precursor is used for radiolabeling, and consequently the reaction volume is reduced to 15 µl. Therefore, the 18 F − solution needs to be concentrated before radiolabeling. The composition of the vial in which the 18 F − is dried is crucial, and glass vials should be avoided because of the presence of fluorophilic silicates on the glass surface. After drying (or concentration), the 18 F − is resuspended with buffered stock solution to initiate the 18 F-19 F IEX.
One notable limitation of this protocol might stem from the acidic radiolabeling conditions. Nevertheless, to date, in our hands, these conditions have not been an issue for most bioligands, as they are generally stable in acidic conditions for a short period of time and many of them are even prepared in acidic conditions 35, 36 . For instance, peptides are typically cleaved from the solid base support and purified under the conditions that are substantially more acidic than those used herein (e.g., deprotection in 80% (vol/vol) trifluoroacetic acid (TFA), pH = −2, purification in 0.1-0.5% (vol/vol) TFA, pH = 1-2; refs. 37,38). REAGENT SETUP Pyridazine-HCl buffer (1.0 M, pH 2.0-2.5) Dissolve 720 µl of pyridazine (10 mmol) in 5 ml of DMF and 2.5 ml of deionized water in a 15-ml conical tube. Adjust the pH by using a pH meter; continue adding diluted HCl (aq., 4 M) until the pH is regulated to 2.0. Adjust the final volume to 10 ml with deionized water to obtain a final concentration of the buffer of 1.0 M. This buffer can be stored at 4 °C for up to 1 month.  crItIcal The pH of this pyridazine buffer may increase after being stored for more than 1 month. If the buffer has been stored for more than 1 week, please make sure to check the buffer pH before radiolabeling. In addition, the buffer should be stored at 4 °C.
The color of the buffer may turn light yellow after prolonged storage, but this color change should not affect the yield of radiolabeling. Aqueous solution of CuSO 4 ·5H 2 O (1.0 M) Dissolve CuSO 4 ·5H 2 O (2.5 g, 10 mmol) with 5 ml of deionized water. Dilute this solution to 10 ml using deionized water to obtain the desired concentration. This solution is stable at room temperature (~20 °C) for at least 3 months. Aqueous solution of sodium ascorbate (1.0 M) Dissolve sodium ascorbate (1.98 g, 10 mmol) with 2 ml of deionized water. Dilute this solution to 10 ml using deionized water to obtain the desired concentration. This solution is stable at room temperature (~20 °C) for at least 3 months. KHF 2 aqueous solution (7.5 mM) Dissolve KHF 2 (5.85 mg, 75 µmol) with 1 ml of deionized water. Dilute this solution to 10 ml using deionized water to obtain the desired concentration. This solution is stable at room temperature (~20 °C) for at least 3 months. NaCl saturated solution Dissolve NaCl (10 g) with 10 ml of deionized water to obtain a saturated solution. This solution is stable at room temperature (~20 °C) for at least 3 months. HCl solution (4 M) Dilute HCl (aq., 37%) with twofold (vol/vol) deionized water to obtain a 4-M HCl aqueous solution. This solution is stable at room temperature (~20 °C) for at least 3 months. EQUIPMENT SETUP Self-assembled m-QMA cartridge manufacture and precondition Cut a 16-gauge × 1 1/2-inch needle with wire cutters and precisely assemble the µ-QMA cartridge between the two parts of the needle. Seal the joints with Parafilm to ensure no possible leaking. Flush the cartridge with 3 ml of deionized water, 3 ml of brine (NaCl-saturated aqueous solution) and 3 ml of deionized water to convert the carbonate-formed QMA into its chloride form. To better understand how the µ-QMA cartridge is assembled, a descriptive picture is available as referenced 18 .  crItIcal A suitable reaction pH (2-2.5) is of paramount importance to give good radiochemical yield for 18 F-labeled organotrifluoroborates. To ensure that the final reaction pH is within the correct range, here we highly recommend using a chloride form instead of the regular carbonate form, which gives strongly basic solution (pH = 11) after elution 40 . The presence of residual carbonate in the QMA may occasionally result in failure of radiosynthesis, and thus it might jeopardize the reproducibility of this radiolabeling protocol. Of note, this self-assembled µ-QMA cartridge can be reused for up to ten cycles of trapping-releasing, and no reconditioning is needed; however, we always recommend flushing the cartridge with 3 ml of deionized water before using it as the 18 F − trap. Sep-Pak C18 light cartridge preconditioning Precondition this cartridge with 6 ml of ethanol, followed by 6 ml of deionized water. HPLC system and radioactivity detector Equip the Agilent 1200 series analytical HPLC system with an Eckert and Ziegler B-FC-3200 NaI detector according to the manufacturer's instructions. Analytical HPLC for quality control (method A) A Phenomenex Jupiter 10-µm C18, 300 Å, 4.6 × 250 mm analytical column is used. The HPLC setup is as follows: solvent A, 0.1% (vol/vol) TFA in water; solvent B, ACN; flow rate, 2 ml/min; and column temperature, 19-21 °C. 
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2|
Continue stirring for 5 min, during which time the solution will become cloudy followed by the formation of a white precipitate, which is the desired N-propargyl-N,N-dimethylammonio-methylboronylpinacolate intermediate product (Fig. 2) .
3|
Filter the resulting precipitate with a sand-core funnel and wash the solid with diethyl ether; retain the solid.
4| Dry the residue under high vacuum to give a fluffy white powder in 95% yield.
5| Convert 50.0 mg of the N-propargyl-N,N-dimethylammonio-methylboronylpinacolate thus synthesized (142.4 µmol)
into the corresponding trifluoroborate (alkynyl-AMBF 3 , 1) by adding a cocktail of KHF 2 (3 M, 300 µl in water), HCl (4 M, 300 µl in water), deionized water (200 µl) and DMF (600 µl).
6|
Allow the reaction to proceed at 45 °C for 2 h, and then quench the reaction by adding 10 µl of NH 4 OH (conc.).
7|
Remove the free fluoride by passing the reaction mixture through a silica gel column. Next, further purify the residue by diethyl ether extraction to obtain a white powder as the chemically pure product in 90% yield (21.2 mg). 14| Add the TATE-azide solution prepared in Step 13 in portions of 50 µl to the mixture prepared in Step 12. The final reaction mixture (Fig. 3) should be a clear solution without any visible precipitate.  crItIcal step The order in which the reagents are added is essential for this step to be successful.
15|
Incubate this reaction mixture at 45 °C for 2 h and directly purify the crude reaction by using the Agilent 1200 HPLC system with method C (see Equipment Setup) to isolate chemically pure AMBF 3 -TATE (compound 3). Confirm and evaluate the identity and chemical purity of the product with LC-MS.
? trouBlesHootInG 16| For convenience and to ensure reproducibility, dilute the purified 19 F-AMBF 3 -TATE in ethanol and store it in aliquots of ~100 nmol in 15 µl for radiolabeling. Please note that these aliquots will be stable in ethanol solution for up to 1 month at room temperature. For longer storage times, the solvent in the aliquots needs to be removed under vacuum.  pause poInt The dry AMBF 3 -conjugated biomolecules should be stored at −20 °C, and it should be used within 6 months.
preparation of the radiosynthesis reaction mixture • tIMInG 30 min 17| Prepare a radiolabeling mixture of AMBF 3 -TATE and 18 F (Fig. 4)  crItIcal step Check the pH of the previously prepared precursor solution with pH strips (0-6) before proceeding with the next step. ? trouBlesHootInG (ii) Prepare the following materials, and then place them into the hot cell.
Quantity Material 2 0.07 ml of saline in a 1-ml PP/PE syringe without needle 2 2 ml of NH 4 OH (aq., 5% (vol/vol)) and 0.5 ml air in a 3-ml PP/PE syringe with a 21-gauge × 2-inch needle 3 4 ml of deionized water in a 5-ml PP/PE syringe without needle 2 0.5 ml of 1:1 saline/ethanol in a 1-ml PP/PE syringe without needle 2 2 ml of saline in a 3-ml PP/PE syringe with a 16-gauge × 1½-inch needle 6 1-ml PP/PE syringes equipped with 21-gauge × 2-inch needles 1 Sep-Pak C18 light cartridge ! cautIon To minimize the radiation dose, properly shield yourself by performing most of the reactions involving radioactivity in a lead-shielded fume hood or a hot cell.  crItIcal step Make sure to always have a back-up sample of each reagent, as the hot cell should not be opened once large quantities of radioactivity (i.e., up to 37 GBq) have been transferred into the hot cell. 
19|
Quench the reaction by adding to it 2 ml of NH 4 OH (5% (vol/vol) aq.) using a 3-ml PP/PE syringe with a 21-gauge × 2-inch needle. Use the same syringe to load the resulting reaction mixture onto a Sep-Pak C18 light cartridge.  crItIcal step The reaction mixture must be loaded into the Sep-Pak C18 light cartridge gently and slowly (one drop every 2 s). In addition, a 2-inch needle is required for this step, as otherwise the crude reaction would not be completely transferred to the cartridge. ? trouBlesHootInG 
21|
Elute the purified product into a glass vial with 1:1 ethanol/saline (0.5 ml), and measure the radioactivity of product by using a Capintec well counter. The radiochemical yield is determined by dividing the radioactivity of finally purified product by the 18 F − being used at the beginning of synthesis.  crItIcal step Do not elute too quickly (the flow rate should be <1 drop every 5 s). In regard to the radiosynthesis, the eluate should be collected in separate fractions every three drops. Measure each fraction using a dose calibrator in the hot cell. The fraction containing the highest concentration of radioactivity should be used for the following studies.
? trouBlesHootInG 22| Dilute the solution obtained at the end of Step 21 with 2 ml of isotonic saline, and then transfer 0.1 ml of the solution thus prepared into another glass vial by using a 1-ml PP/PE syringe equipped with a 21-gauge × 2-inch needle. ! cautIon By starting with 37 GBq of radioactivity (Step 17A(i-vi)), generally >7.4 GBq of 18 F-labeled product will be obtained in 2 ml of saline solution. To avoid unnecessary exposure to radiation, always take out the minimum portion of the radioactive product based on the quantities required for subsequent studies (such as imaging or biodistribution experiments).
23| Take the vial with 0.1 ml of the solution out of the hot cell. Dilute the product with an additional 5-10 ml of isotonic saline to obtain a solution that can be readily injected for biological evaluation.  crItIcal step The final concentration of ethanol in the resulting solution should not exceed 10% (vol/vol).
24|
Remove a small portion from the solution obtained after implementing Step 23 to determine the radiochemical purity of the product with the analytical HPLC system (method A, see Equipment Setup).
? trouBlesHootInG Troubleshooting advice can be found in table 1. 18 F-labeled product should be produced in 45 min, with a specific activity higher than 27.8 GBq/µmol (0.75 Ci/µmol). For both radiolabeling procedures, the radiochemical purity, which is determined by HPLC analysis, should be higher than 98% (Fig. 5) , thus eliminating the need for further HPLC purification. If the radiochemical purity of the product is <95%, a second Sep-Pak purification (Steps 19-21) would be recommended to improve the purity. A representative PET imaging of 18 F-AMBF 3 -TATE is shown in Figure 6 here to illustrate the general in vivo performance of AMBF 3 -TATE. The tracer specifically accumulated into the tumor, whereas the background radioactivity was rapidly cleared mainly via the kidneys to the bladder. Some gut and gallbladder accumulation occurs because of some hepatobiliary excretion of the tracer. The concentration of the precursor is not sufficient
The final concentration of the precursor is suggested to be no less than 1 mM. Instead of weighing the HPLC-purified AmBF 3 conjugates with a balance, which is not accurate because of contamination (e.g., of TFA salts), we recommend the use of UV absorbance at a certain wavelength (e.g., 277 nm for AMBF 3 -TATE) to determine the quantity of the AMBF 3 conjugates
Low isolated radiochemical yield (<10%)
The pH of the radiolabeling reaction is not suitable
The final concentration of the pyridazine buffer should be no less than 100 mM
